Non-Current Assets

Indefinite-Lived Research and Development Assets

International Paper Indefinite-Lived Research and Development Assets decreased by 97.9% to $5.00M in Q4 2025 compared to the prior quarter. Over 2 years (FY 2023 to FY 2025), Indefinite-Lived Research and Development Assets shows a downward trend with a -82.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ4 2023
Last reportedQ4 2025Feb 27, 2026

How to read this metric

An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.

Detailed definition

This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...

Peer comparison

Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.

Metric ID: indefinite_lived_rd_assets

Historical Data

3 periods
 Q4 '23Q4 '24Q4 '25
Value$162.00M$240.00M$5.00M
QoQ Change+48.1%-97.9%
YoY Change+48.1%-97.9%
Range$5.00M$240.00M
Avg YoY Growth-24.9%
Median YoY Growth-24.9%

Indefinite-Lived Research and Development Assets at Other Companies

Frequently Asked Questions

What is International Paper's indefinite-lived research and development assets?
International Paper (IP) reported indefinite-lived research and development assets of $5.00M in Q4 2025.
What is the long-term trend for International Paper's indefinite-lived research and development assets?
Over 2 years (2023 to 2025), International Paper's indefinite-lived research and development assets has grown at a -82.4% compound annual growth rate (CAGR), from $162.00M to $5.00M.
What does indefinite-lived research and development assets mean?
The value of ongoing research projects acquired from other companies that are not yet ready for sale.